Coherus Oncology/$CHRS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Coherus Oncology
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
Ticker
$CHRS
Sector
Primary listing
Employees
145
Headquarters
Website
Coherus Oncology Metrics
BasicAdvanced
$214m
0.91
$1.52
1.02
-
Price and volume
Market cap
$214m
Beta
1.02
52-week high
$2.62
52-week low
$0.71
Average daily volume
1.2m
Financial strength
Current ratio
1.557
Quick ratio
1.432
Long term debt to equity
66.74
Total debt to equity
47.247
Interest coverage (TTM)
-18.50%
Profitability
EBITDA (TTM)
-163.391
Gross margin (TTM)
68.06%
Net profit margin (TTM)
397.30%
Operating margin (TTM)
-356.53%
Revenue per employee (TTM)
$320,000
Management effectiveness
Return on assets (TTM)
-32.80%
Return on equity (TTM)
329.36%
Valuation
Price to earnings (TTM)
0.912
Price to revenue (TTM)
3.625
Price to book
2.73
Price to tangible book (TTM)
6.49
Price to free cash flow (TTM)
-1.025
Free cash flow yield (TTM)
-97.58%
Free cash flow per share (TTM)
-1.356
Growth
Revenue change (TTM)
47.99%
Earnings per share change (TTM)
-234.17%
3-year revenue growth (CAGR)
-36.53%
10-year revenue growth (CAGR)
2.51%
3-year earnings per share growth (CAGR)
-24.06%
10-year earnings per share growth (CAGR)
-13.41%
What the Analysts think about Coherus Oncology
Analyst ratings (Buy, Hold, Sell) for Coherus Oncology stock.
Coherus Oncology Financial Performance
Revenues and expenses
Coherus Oncology Earnings Performance
Company profitability
Coherus Oncology News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs